Peptides for Weight loss
The peptides people most often research for weight loss, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 8
- With human trials
- 8
- FDA approved (any use)
- 4
- SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40934115Human1978Animal160Summarised14FDA approved (Ozempic, Wegovy, Rybelsus)For weight lossOverview
- TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4Arthritis & rheumatology 2026, PMID 41903163Human990Animal49Summarised16FDA approved (Mounjaro, Zepbound)For weight lossOverview
- RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954Human71Animal7Summarised13Investigational · phase 3For weight lossOverview
- SermorelinGHRH analogHuman observational evidence, 3 of 4Metabolism: clinical and experimental 1997, PMID 9005976Human4Animal0Summarised1Compounded by prescriptionFor weight lossOverview
- hCGGonadotropinHuman RCT evidence, 4 of 4The Journal of clinical endocrinology and metabolism 2002, PMID 12107212Human156Animal124Summarised5FDA approved (prescription only)For weight lossOverview
- OrforglipronOral small-molecule GLP-1 agonistHuman RCT evidence, 4 of 4Lancet 2026, PMID 41275875Human55Animal0Summarised9FDA approved (Foundayo, Apr 2026)For weight lossOverview
- CJC-1295GHRH analogHuman observational evidence, 3 of 4Substance use & misuse 2016, PMID 26771670Human2Animal1Summarised1Not FDA approved · research chemicalFor weight lossOverview
- MOTS-cMitochondrial-derived peptideHuman RCT evidence, 4 of 4Scientific reports 2021, PMID 34413391Human12Animal13Summarised4PCAC voted 7–5 for 503A (Jul 2026)For weight lossOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What the weight-loss goal means medically
MedlinePlus ties weight control to the balance between calories taken in and calories used, and says extra weight raises the risk of conditions including type 2 diabetes and heart disease.[9]
It adds that more than 70 percent of US adults are overweight or have obesity, so weight-related health concerns reach a very large group.[9]
How much weight people lost in trials of each weight-loss peptide
Semaglutide shows 1,978 human-only papers and 209 randomised trials, tirzepatide 990 and 113, whereas AOD-9604, SLU-PP-332 and 5-amino-1MQ have only animal results in the evidence files.
Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); semaglutide human only 1978, animal only 160, rct 209; tirzepatide human only 990, animal only 49, rct 113; retatrutide human only 71, animal only 7, rct 6; orforglipron human only 55, animal only 0, rct 12; mots-c human only 12, animal only 13, rct 1. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.
In the STEP 1 trial of semaglutide, the mean weight change at 68 weeks was -14.9% against -2.4% on placebo.[10]
In tirzepatide's 72-week trial in adults with obesity, the mean weight change was -15.0% at 5 mg, -19.5% at 10 mg and -20.9% at 15 mg weekly, against -3.1% on placebo.[11]
Head to head against semaglutide at 72 weeks, tirzepatide produced a mean weight change of -20.2% against -13.7% (open-label trial, maximum tolerated doses).[12]
Retatrutide, which is not approved, reached a mean weight change of -24.2% in the 12 mg group at 48 weeks in a phase 2 trial, against -2.1% on placebo.[13]
Cagrilintide plus semaglutide produced a mean weight change of -20.4% at 68 weeks in a phase 3 trial, against -3.0% on placebo.[14]
Orforglipron, a GLP-1 drug taken by mouth, produced mean weight changes of -7.5% at 6 mg, -8.4% at 12 mg and -11.2% at 36 mg at 72 weeks, against -2.1% on placebo.[15]
hCG, a hormone often promoted for dieting, failed to beat placebo in a controlled trial and a review found no evidence it works for obesity.[16]
Research peptides for weight loss: AOD-9604, 5-amino-1MQ and SLU-PP-332
AOD-9604, a fragment of growth hormone, reduced weight gain in rats, an animal-only result.[17]
SLU-PP-332 raised energy expenditure in mice, and there are no human trials cited for it.[18]
For 5-amino-1MQ the cached weight-loss result is from mice: an NNMT inhibitor combined with a low-fat diet produced marked loss of adiposity and weight in diet-induced obese mice.[19]
What the FDA labels say about approved weight drugs
Zepbound's label lists chronic weight management in adults with obesity or overweight with a weight-related condition, plus obstructive sleep apnea in adults with obesity.[20]
The Wegovy label adds a cardiovascular-risk indication for adults with established heart disease and obesity or overweight.[21]
The hCG label states in capitals that hCG is not demonstrated to be effective for obesity.[22]
Common questions
What are the best peptides for fat loss?
Retatrutide is not approved, but in its phase 2 trial the 12 mg group lost an average of 24.2% of body weight at 48 weeks; approved drugs such as semaglutide and tirzepatide have larger and longer trials behind them.[13]
Do peptide injections for weight loss work?
Semaglutide and tirzepatide injections cut average body weight in randomised trials, whereas hCG did not beat placebo.[10]
Is peptide therapy for weight loss approved by the FDA?
Several incretin products are labelled for weight management, such as Zepbound, but the hCG label says it has not been shown effective for obesity.[20]
Is there a peptide stack for fat loss?
No trial of a fat-loss stack is cached; the combination with real trial data is cagrilintide plus semaglutide.[14]
Does hCG help weight loss?
Randomised trials and a review found no weight-loss benefit over placebo.[23]
Is orforglipron (Foundayo) approved for weight loss?
Yes. The Foundayo label lists weight reduction and long-term maintenance in adults with obesity, or with overweight plus a weight-related condition, alongside a reduced-calorie diet and more physical activity.[24]
Explore nearby goals
Sources
- 1Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 2Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 3Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
- 4Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 5A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency.The Journal of clinical endocrinology and metabolism · 2002PMID 12107212Accessed 2 Oct 2026
- 6Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 7Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse · 2016PMID 26771670Accessed 2 Oct 2026
- 8Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 9Official web pageOfficial web page · web page
- 10Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 11Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 13Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 14Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
- 15Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 16The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis.British journal of clinical pharmacology · 1995PMID 8527285Accessed 2 Oct 2026
- 17Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 18A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 19Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
- 20ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 21WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 22NOVAREL ® (chorionic gonadotropin) for injection, for intramuscular use Initial U.S. Approval: 1974FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 23Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study.The American journal of clinical nutrition · 1976PMID 786001Accessed 2 Oct 2026
- 24FOUNDAYO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.